ANZIBDC
ANZIBDC
  • Home
  • About Us
    • Our Governance
    • Gallery
    • Annual reports
  • Projects
  • News
  • Partner with us
  • Contact Us
  • Members
  • More
    • Home
    • About Us
      • Our Governance
      • Gallery
      • Annual reports
    • Projects
    • News
    • Partner with us
    • Contact Us
    • Members
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out


Signed in as:

filler@godaddy.com

  • Home
  • About Us
    • Our Governance
    • Gallery
    • Annual reports
  • Projects
  • News
  • Partner with us
  • Contact Us
  • Members

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

The Study of TOfacitinib for the treatment of chronic PouchITis (STOPit)

Lead investigators: A/Prof Jake Begun, Dr Emi Khoo


Sites: Mater Hospital Brisbane (lead site). This study will be conducted at ~16 sites across QLD, NSW, VIC, SA and WA including 12 ANZ IBD consortium sites. 


Project overview and aims:

Pouchitis is the most common complication following a total proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis. Despite the curative intent of proctocolectomy, up to 80% of patients develop inflammation of the pouch post-surgery known as pouchitis. Antibiotics remain the first line treatment option, however a small proportion of individuals develop chronic pouchitis, which is either refractory to antibiotic therapy or dependent on antibiotics for symptomatic relief. 


Unfortunately, there are limited studies of the effectiveness of treatments for chronic pouchitis resulting in a lack of guidance for clinicians treating these patients.  The STOPit trial is a randomized, double-blind, placebo-controlled study to test whether tofacitinib (which has recently been approved for treatment of ulcerative colitis) is an effective treatment for chronic pouchitis.


Recruitment:

We are aiming to recruit ~120 patient who meet the inclusion criteria:

  • Adult patients age 18 to 65 
  • Previous diagnosis of ulcerative colitis (UC) and have undergone total proctocolectomy and ileal pouch-anal anastomosis (IPAA)
  • Chronic or recurrent pouchitis ( > 4 weeks of antibiotics in the previous 12 months OR pouchitis that is refractory to antibiotic therapy)
  • A total modified pouchitis disease activity index (mPDAI) score > 5 with endoscopic evidence of active disease 


The results of this study will inform whether tofacitinib is effective and safe for treatment of chronic pouchitis.

  • Privacy Policy
  • Terms and Conditions

ANZIBDC

Copyright © 2023 ANZIBDC - All Rights Reserved.

Powered by GoDaddy Website Builder

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept